Susceptibility of Primary HTLV-1 Isolates from Patients with HTLV-1-Associated Myelopathy to Reverse Transcriptase Inhibitors
Open Access
- 5 May 2011
- Vol. 3 (5), 469-483
- https://doi.org/10.3390/v3050469
Abstract
Since human T-lymphotropic virus type 1 (HTLV-1)-associated diseases are associated with a high HTLV-1 load, reducing this load may treat or prevent disease. However, despite in vitro evidence that certain nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs) are active against HTLV-1, in vivo results have been disappointing. We therefore assayed the sensitivity of HTLV-1 primary isolates to a panel of RT inhibitors. HTLV-1 primary isolates were obtained, pre- and post- NRTI treatment, from patients with HTLV-1-associated myelopathy. Sensitivity to azidothymidine (AZT), lamivudine (3TC), tenofovir (TDF) and three phosphonated carbocyclic 2’-oxa-3’aza nucleosides (PCOANs) was assessed in a RT inhibitor assay. With the exception of 3TC, HTLV RT from primary isolates was less sensitive to all tested inhibitors than HTLV-1 RT from MT-2 cells. HTLV-1 RT from primary isolates and from chronically infected, transformed MT-2 cells was insensitive to 3TC. Sensitivity of primary isolates to RT inhibitors was not reduced following up to 12 months of patient treatment with AZT plus 3TC. The sensitivity of HTLV-1 primary isolates to NRTIs differs from that of cell lines and may vary among patients. Failure of NRTIs to reduce HTLV-1 viral load in vivo was not due to the development of phenotypic NRTI resistance. AZT and the three PCOANs assayed all consistently inhibited primary isolate HTLV-1 RT.Keywords
This publication has 23 references indexed in Scilit:
- The host genomic environment of the provirus determines the abundance of HTLV-1–infected T-cell clonesBlood, 2011
- Protection by Herpes Simplex Virus Glycoprotein D against Fas-mediated ApoptosisPublished by Elsevier BV ,2003
- Susceptibility of Human T Cell Leukemia Virus Type I to Nucleoside Reverse Transcriptase InhibitorsThe Journal of Infectious Diseases, 2003
- Enantioselective Syntheses and Cytotoxicity of N,O-NucleosidesJournal of Medicinal Chemistry, 2003
- Lamivudine Resistance in Human T-Cell Leukemia Virus Type 1 May Be Due to a Polymorphism at Codon 118 (V→I) of the Reverse TranscriptaseAntimicrobial Agents and Chemotherapy, 2003
- Effect of Lamivudine on Transmission of Human T-Cell Lymphotropic Virus Type 1 to Adult Peripheral Blood Mononuclear Cells In VitroAntimicrobial Agents and Chemotherapy, 2002
- Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.2002
- Susceptibility of Human T Cell Leukemia Virus Type 1 to Reverse‐Transcriptase Inhibitors: Evidence for Resistance to LamivudineThe Journal of Infectious Diseases, 2001
- Chimeric Matrix Proteins Encoded by Defective Proviruses with Large Internal Deletions in Human T-Cell Leukemia Virus Type 1-Infected HumansJournal of Virology, 2000
- Prospective Study of HTLV-I Infection in an Initially Asymptomatic CohortJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999